HBV

Hepatitis B virus (HBV) research compounds act on viral replication and on host steps of infection. HBV is a small enveloped DNA virus that copies its genome by reverse transcription of a pregenomic RNA inside the viral nucleocapsid. Nucleoside analogs such as telbivudine are phosphorylated in cells and then interfere with this reverse transcription step. Capsid assembly modulators work elsewhere in the cycle, and heteroaryldihydropyrimidines of the BAY41-4109 racemic type were shown to deplete nucleocapsids, while morphothiadin is a later capsid-directed compound. Virus entry depends on the bile acid transporter sodium taurocholate cotransporting polypeptide (NTCP), identified as the receptor for HBV. Catalpol is an iridoid glycoside listed here for reported activity in HBV cell models.

Items 101-125 of 162

  • HBV/HDV-IN-3
    Cat. No.
    A50975

    HBV/HDV-IN-3

    HBV/HDV-IN-3 is a dual inhibitor targeting Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV), demonstrating an effective EC50 of less than 50 nM against HBV. This compound shows significant antiviral activity and is suitable for research applications focused on the development of therapeutics for HBV and HDV infections. Its effectiveness in inhibiting both viruses makes it a valuable tool for exploring antiviral strategies.

    25 mg
    $1,815.00
    50 mg
    $2,355.00
    All 3 sizes
  • HBV-IN-34
    Cat. No.
    A50976

    HBV-IN-34

    HBV-IN-34 is a potent inhibitor of HBsAg production, primarily targeting hepatitis B virus (HBV) replication. It demonstrates significant in vitro anti-HBV activity, with an EC50 of 0.018 μM for HBV DNA and 0.044 μM for HBsAg. This compound is valuable for research applications focused on understanding HBV biology and developing antiviral therapies aimed at reducing HBV load.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • HBV-IN-11
    Cat. No.
    A50980

    HBV-IN-11

    HBV-IN-11 is a potent inhibitor of hepatitis B surface antigen (HBsAg) secretion, demonstrating an EC50 value of 0.46 µM. This compound is valuable for research applications aimed at understanding and blocking hepatitis B viral replication and infection. Its efficacy in modulating HBsAg levels makes it a critical tool for studying therapeutic strategies against hepatitis B virus (HBV) persistence and pathogenesis.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • AB-506
    Cat. No.
    A50981

    AB-506

    AB-506 is an orally bioavailable inhibitor of hepatitis B virus (HBV) replication that targets the viral core protein. By binding to the HBV core protein, AB-506 facilitates capsid assembly and inhibits the encapsidation of HBV pgRNA. This compound is intended for use in research related to chronic hepatitis B (CHB) and provides a valuable tool for studies on viral replication mechanisms and potential therapeutic interventions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • (S)-Canocapavir
    Cat. No.
    A50982

    (S)-Canocapavir

    Synonyms: (S)-ZM-H1505R

    (S)-Canocapavir is an isomer of the antiviral agent Canocapavir, specifically targeting the HBV core protein. It functions as an HBV capsid inhibitor by binding to the hydrophobic pocket at the dimer-dimer interface of the HBV core protein (HBc). This binding promotes the intracellular accumulation of nonfunctional HBV capsids, thereby disrupting viral replication and interfering with the interaction between HBc and the HBV large surface protein. (S)-Canocapavir is relevant for research into hepatitis B virus (HBV) infection and its associated pathologies.

    1 mg
    $155.00
    5 mg
    $395.00
    All 5 sizes
  • HBV-IN-25
    Cat. No.
    A50983

    HBV-IN-25

    HBV-IN-25 is a potent HBV cccDNA reducer with demonstrated oral bioavailability. It exhibits anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 possesses excellent aqueous solubility (LYSA > 452 μg/mL) and favorable pharmacokinetic properties, with no observed cellular toxicity. This compound is suited for research applications focused on hepatitis B virus infection and its associated pathologies.

    Out of stock

    All 3 sizes
  • HBV-IN-29
    Cat. No.
    A50984

    HBV-IN-29

    HBV-IN-29 is a flavone derivative that functions as a potent inhibitor of covalently closed circular DNA (cccDNA). Targeting cccDNA, which serves as the template for viral RNA transcription and subsequent viral DNA synthesis, HBV-IN-29 demonstrates significant potential for studying hepatitis B virus (HBV) infection and the mechanisms underlying viral replication. This compound is essential for research aimed at understanding HBV pathogenesis and evaluating therapeutic interventions.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • Sanggenol P
    Cat. No.
    A50985

    Sanggenol P

    Sanggenol P is a flavonoid with demonstrated anti-hepatitis B virus (HBV) activity, specifically targeting HBV-infected HepG2.2.15 cell lines in vitro. This compound may serve as a valuable tool in the research of HBV-related therapies and the development of antiviral strategies. Its potential role in inhibiting HBV replication highlights its relevance for further studies in hepatology and virology.

    1 mg
    $330.00
    5 mg
    $850.00
    All 3 sizes
  • HBV-IN-13
    Cat. No.
    A50988

    HBV-IN-13

    HBV-IN-13 is a potent inhibitor of hepatitis B surface antigen (HBsAg), targeting the early stages of hepatitis B virus infection. This compound demonstrates significant antiviral activity, making it a valuable tool for research focused on hepatitis B virus therapies and vaccine development. hbv-inhibitors such as HBV-IN-13 can aid in the exploration of mechanisms of viral assembly and release, facilitating advancements in the understanding of chronic hepatitis B management.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • HBV Seq1 aa:18-27
    Cat. No.
    A50989

    HBV Seq1 aa:18-27

    HBV Seq1 aa:18-27 is a peptide fragment derived from the hepatitis B virus (HBV) core antigen, specifically representing amino acids 18 to 27. This fragment is valuable for research applications focused on HBV immune response, vaccine development, and diagnostic assays. Its use in studies can aid in the understanding of HBV pathogenesis and potential therapeutic strategies.

    Out of stock

    All 3 sizes
  • HBV/HDV-IN-4 hydrochloride
    Cat. No.
    A50991

    HBV/HDV-IN-4 hydrochloride

    HBV/HDV-IN-4 hydrochloride is a dual inhibitor targeting both Hepatitis B virus (HBV) and Hepatitis D virus (HDV), demonstrating potent activity with an EC50 of less than 50 nM against HBV. This compound serves as a valuable tool for investigating therapeutic strategies in viral hepatitis research and offers potential for the development of antiviral agents against these challenging infections.

    Out of stock

    All 3 sizes
  • AB-452
    Cat. No.
    A50994

    AB-452

    AB-452 is a dihydroquinolizinone (DHQ) analogue that functions as a potent HBV RNA destabilizer. It effectively inhibits PAPD5 and PAPD7 proteins in vitro and demonstrates significant in vivo efficacy in chronic HBV mouse models. This compound serves as a valuable tool for the study of hepatitis B virus pathology and therapeutic interventions.

    Out of stock

    All 3 sizes
  • Apigenin-4'-α-L-rhamnoside
    Cat. No.
    A50997

    Apigenin-4'-α-L-rhamnoside

    Apigenin-4'-α-L-rhamnoside is a potent inhibitor of Hepatitis B virus (HBV) primarily targeting the secretion of HBV surface antigen (HBsAg). This compound has demonstrated significant efficacy in reducing HBsAg levels in HepG2.2.15 cell lines. Its application in research facilitates the exploration of HBV pathogenesis and potential therapeutic strategies for hepatotropic viral infections.

    1 mg
    $480.00
    All 1 sizes
  • Oleana-2,12-dien-28-oic acid
    Cat. No.
    A50998

    Oleana-2,12-dien-28-oic acid

    Oleana-2,12-dien-28-oic acid is a potent HBV-DNA inhibitor that also targets HBsAg and HBeAg. This compound demonstrates significant antiviral activity, making it a valuable tool for studying hepatitis B virus infections. It is suitable for research applications focused on the mechanisms of HBV replication and potential therapeutic interventions.

    5 mg
    $35.00
    10 mg
    $55.00
    All 5 sizes
  • (-)-Carbovir
    Cat. No.
    A50999

    (-)-Carbovir ((-)-NSC 614846)

    Synonyms: (-)-NSC 614846

    (-)-Carbovir is a potent inhibitor of Hepatitis B virus (HBV) replication. It exhibits antiviral activity by specifically targeting and interfering with HBV polymerase, thereby disrupting viral nucleic acid synthesis. This compound is primarily used in research contexts focused on developing therapeutic strategies for HBV infections and understanding the mechanisms of viral resistance.

    25 mg
    $55.00
    50 mg
    $105.00
    All 4 sizes
  • Bentysrepinine
    Cat. No.
    A51000

    Bentysrepinine

    Synonyms: Y101

    Bentysrepinine is an orally active inhibitor of the hepatitis B virus (HBV) that exhibits potent antiviral activity. It demonstrates favorable pharmacokinetic properties, with notable bioavailability across different species, including rats, dogs, and monkeys, and shows no accumulation in monkeys after 90 days of administration. This compound is being investigated for its potential applications in antiviral therapies and hepatitis research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • HBV-IN-12
    Cat. No.
    A51001

    HBV-IN-12

    HBV-IN-12 is a highly effective inhibitor of hepatitis B surface antigen (HBsAg) with an EC50 range of 0.001 μM to 0.05 μM, demonstrating significant inhibition of HBsAg. Additionally, HBV-IN-12 exhibits anti-HBV DNA activity with an EC50 range of 0.001 μM to 0.02 μM. This compound serves as a valuable tool for research applications aimed at understanding hepatitis B virus pathogenesis and developing antiviral therapeutics.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Daplusiran
    Cat. No.
    A51002

    Daplusiran

    Daplusiran is a small interfering RNA (siRNA) designed to target and promote the degradation of hepatitis B virus (HBV) mRNAs. By inhibiting the replication of HBV, it serves as a vital tool in the development of therapeutic strategies for HBV-related diseases. Research applications include studies focused on liver disease and antiviral interventions.

    Out of stock

    All 3 sizes
  • Periglaucine B
    Cat. No.
    A51003

    Periglaucine B

    Synonyms: (+)-Periglaucine B

    Periglaucine B is an alkaloid that functions as an HBsAg inhibitor. Isolated from Pericampylus glaucus, it effectively inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells, exhibiting an IC50 of 0.47 mM. This compound is valuable for research focused on hepatitis B virus pathology and therapeutic interventions.

    5 mg
    $605.00
    All 1 sizes
  • HBV-IN-6
    Cat. No.
    A51004

    HBV-IN-6

    HBV-IN-6 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 value of 44 nM. This compound effectively interferes with viral replication, making it a valuable tool for research focused on HBV-related mechanisms and therapeutic strategies. Its efficacy underscores its potential application in developing effective treatments for HBV infections.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • Antiviral agent 38
    Cat. No.
    A51006

    Antiviral agent 38

    Antiviral Agent 38 is a potent inhibitor of the hepatitis B virus (HBV). This compound demonstrates significant antiviral activity, making it a valuable tool for research on HBV infections and their associated pathologies. Its efficacy positions it as an important reagent for studying HBV biology and potential therapeutic interventions.

    1 mg
    $65.00
    5 mg
    $155.00
    All 5 sizes
  • HBV-IN-38
    Cat. No.
    A51007

    HBV-IN-38

    HBV-IN-38 is an HBV DNA inhibitor, exhibiting an effective concentration (EC50) of ≤100 nM. This compound is primarily utilized in research to investigate the mechanisms of hepatitis B virus (HBV) infections and to evaluate potential therapeutic interventions against HBV replication.

    Out of stock

    All 3 sizes
  • Rolicyprine
    Cat. No.
    A51008

    Rolicyprine

    Synonyms: EX-4883

    Rolicyprine is a potent inhibitor of Hepatitis B Virus (HBV) that also exhibits neuroprotective activity. It has been shown to alleviate depressive symptoms and promote neuroregeneration, making it relevant for neuropsychiatric research. Additionally, Rolicyprine demonstrates potential in alleviating anxiety, indicating its applicability in studies related to mood disorders and HBV infections.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Erythrocentaurin
    Cat. No.
    A51009

    Erythrocentaurin

    Erythrocentaurin is a natural compound that acts as an inhibitor of the hepatitis B virus (HBV). It exhibits potent antiviral activity, making it a promising candidate for research focused on HBV treatment and management. This compound can be utilized in studies aimed at understanding the mechanisms of HBV replication and the development of novel therapeutic strategies.

    1 mg
    $305.00
    5 mg
    $950.00
    All 2 sizes
  • L-Fd4A
    Cat. No.
    A51011

    L-Fd4A

    L-Fd4A is an adenine derivative that inhibits both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) with effective concentrations (EC50) of 1.5 μM and 1.7 μM, respectively. This compound demonstrates promising antiviral activity while exhibiting low cytotoxicity, making it suitable for research applications in studying HIV and HBV inhibition mechanisms.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes

Items 101-125 of 162

Added to your cart

View Cart Checkout

    Loading...